Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acheson departs FDA

This article was originally published in The Tan Sheet

Executive Summary

David Acheson, the agency's first associate commissioner for foods leaves for a position in a new consultancy founded by former Health and Human Services Secretary Mike Leavitt. Acheson, appointed to associate commissioner in May 2007, said in an Aug. 7 e-mail that he will focus on food safety and the global food supply chain at Leavitt Partners in Washington. The role of the associate commissioner for foods is unclear following a recently announced FDA reorganization that will create a deputy commissioner for food (1"The Tan Sheet" July 13, 2009)

You may also be interested in...



FDA Creates Food Czar In Agency-Wide Reorganization

FDA will create a new position to oversee all food safety activities in response to recent food security problems and as part of a proposed agency-wide reorganization

OTC Naloxone Pioneer Emergent BioSolutions Puts Papa At Helm As It Navigates Strategy Shift

Like his previous move, Papa joins a pharma firm making a significant organizational shift to cut costs and increase revenues after extended period of higher spending and slowing income.

Blueprint RETreats As It Sells US Gavreto Rights To Rigel

After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel